Author: Vikas Kumar
10 January 2023
The pulmonary edema therapeutics market is expected to witness a CAGR of around 3% during the forecast period. A condition known as pulmonary edema is brought on by an accumulation of fluid in the lungs. The numerous air sacs in the lungs become blocked with this fluid, making breathing difficult. Supplemental oxygen is usually given as the first line of treatment for acute pulmonary edema through a nasal cannula, a flexible plastic tube with two openings that deliver oxygen to each nostril. Diuretics, blood pressure medications, morphine, and inotropes may be prescribed, depending on the severity of the condition and the underlying cause of pulmonary edema.
Furthermore, it is anticipated that the global market for pulmonary edema therapeutics will expand due to the rising incidence of heart failure, a major cause of pulmonary edema. For instance, as per the Places for Infectious prevention and Anticipation, in 2020, around 6.2 million grown-ups in the U.S. had a cardiovascular breakdown.
For a detailed analysis of the Global Pulmonary Edema Therapeutics Market browse through- https://univdatos.com/report/pulmonary-edema-therapeutics-market/
On the basis of type, the market is categorized into cardiogenic pulmonary edema and non-cardiogenic pulmonary edema. Among these, cardiogenic pulmonary edema to hold a significant share of the market in 2020. This is mainly due to the increasing rate of heart failure because it is one of the most common causes of cardiogenic pulmonary edema and it is one of the most common causes of death among adults globally.
Based on the distribution channel, the pulmonary edema therapeutics market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies category is to witness higher adoption of pulmonary edema therapeutics during the forecast period. This is mainly due to the availability of skilled healthcare professionals & the safety & efficacy during the treatment procedures also rising hospital administration of pulmonary edema patients globally are the major factors for the growth of the segment.
Request for a sample of the report browse through- https://univdatos.com/get-a-free-sample-form-php/?product_id=32723
For a better understanding of the market adoption of the pulmonary edema therapeutics industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. The high prevalence of risk factors and the growing acceptance of medications to treat pulmonary edema are factors for the growth of the market in the region. In addition, the region’s abundance of clinics and accessibility to technologically advanced instruments are further propelling the market’s expansion. Additionally, the Centers for Disease Control and Prevention estimate that heart disease accounts for 647,000 annual deaths in the US, or 1 in 4 deaths.
Some of the major players operating in the market include AbbVie Inc., Apotex Inc., Bausch Health Companies Inc., CMP Pharma Inc., Johnson and Johnson, Lupin Ltd., Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd.
Global Pulmonary Edema Therapeutics Market Segmentation
Market Insight, by Drug Class
Market Insight, by Type
Market Insight, by Distribution Channel
Market Insight, by Region
Top Company Profiles
Get a call back
